Our mission is to offer national screening programs of the highest quality to the population residing in Cyprus, for the best possible start in every child's life.
The program’s objective is the timely diagnosis of chromosomal abnormalities in the foetus and is offered to all women in their first trimester of pregnancy. The test is partly based on the measurement of maternal blood biochemical markers from a sample taken from the pregnant woman. These blood samples are collected by all the gynaecologists in Cyprus and subsequently sent to the Center’s Clinical Lab whereby the blood measurements are made. The blood results, together with ultrasonographic measurements of the foetus, specifically the nuchal translucency or NT, and the maternal age are finally used to calculate the chromosomal abnormality risk associated with the foetus. The most commonly occurring chromosomal abnormality is Trisomy 21, otherwise known as Down’s Syndrome. The risk given through this screening test is the most relevant piece of information in helping the parents decide whether they will need prenatal diagnostic testing.
Click on the following links for further information: